Skip to main content

Advertisement

SpringerLink
Log in

Adjuvant therapy approaches to breast cancer: Should taxanes be incorporated?

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

The triplet of docetaxel, doxorubicin, and cyclophosphamide (TAC) has emerged as an alternative chemotherapy regimen for adjuvant management of node-positive breast cancer. Based on recently reported 3-year data from the Breast Cancer International Research Group (BCIRG) 001, disease-free survival was significantly higher in patients who underwent adjuvant chemotherapy with TAC rather than the established regimen of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC). TAC reduced the risk of disease recurrence in estrogen receptor-positive and -negative patients. Whereas overall survival was not significantly different between the two groups, TAC led to a significant reduction in mortality in the subset of patients with one to three involved axillary lymph nodes. Overall, these interim BCIRG 001 results, coupled with those from Cancer and Leukemia Group B-9344 and National Surgical Adjuvant Breast and Bowel Project (NSABP) B-28 (phase III trials of sequential adjuvant chemotherapy with doxorubicin and cyclophosphamide followed by paclitaxel), suggest that taxanes are a valuable component of adjuvant chemotherapy for patients with node-positive breast cancer, including those with estrogen receptor positivity and/or extensive lymph node involvement. Accumulating data in the neoadjuvant setting lend further support to the view that the taxanes confer clinically meaningful benefits in the management of early-stage breast cancer. Such ongoing studies as NSABP B-30 will be instrumental in establishing the relative merits of sequential versus concurrent taxane-anthracycline adjuvant regimens for patients with node-positive breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Chan S, Friedrichs K, Noel D, et al.: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999, 17:2341–2354.

    PubMed  CAS  Google Scholar 

  2. Nabholtz J-M, Gelmon K, Bontenbal M, et al.: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996, 14:1858–1867.

    PubMed  CAS  Google Scholar 

  3. Nabholtz JM, Senn HJ, Bezwoda WR, et al.: Prospective randomized trial of docetaxel versus mitoxantrone plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999, 17:1413–1424.

    PubMed  CAS  Google Scholar 

  4. Peretz T, Sulkes A, Chollet P, et al.: A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC). Eur J Cancer 1995, 31(Suppl 5):S75.

    Article  Google Scholar 

  5. Seidman AD, Tiersten A, Hudis C, et al.: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995, 13:2575–2581.

    PubMed  CAS  Google Scholar 

  6. Sjöström J, Blomqvist C, Mouridsen H, et al.: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomized phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999, 35:1194–1201.

    Article  PubMed  Google Scholar 

  7. Nabholtz J-M, Pienkowski T, Mackey J, et al.: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study [abstract]. Proc ASCO 2002, 21:36a. se 33-month follow-up data from the phase III BCIRG 001 trial demonstrate a significant 8% absolute improvement in disease-free survival for adjuvant therapy with TAC versus FAC. Overall survival was similar between the two groups, with a 5% absolute improvement for TAC versus FAC; however, in the subset of patients with one to three positive nodes, TAC was associated with significantly higher overall survival compared with FAC

    Google Scholar 

  8. Mackey JR, Cantin J, Chang J, et al.: Role of hematopoietic growth factors in the prevention of neutropenic complications for breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide (TAC): results of a randomized double-blind phase III trial—BCIRG 004 [abstract]. Proc ASCO 2001, 20:10a. this phase III trial, the prophylactic use of granulocyte-colony stimulating factor reduced the incidence of febrile neutropenia to 6.7% in patients receiving TAC for metastatic breast cancer

    Google Scholar 

  9. Henderson IC: Adjuvant chemotherapy: taxanes—the ‘pro’ position. Presentation at the National Institutes of Health Consensus Conference: Adjuvant Therapy for Breast Cancer. Bethesda, MD, November 1–3, 2000. http://consensus.nighgov/cons/114/114_abstract.pdf.

  10. Henderson IC, Berry D, Demetri G, et al.: Improved diseasefree (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer [abstract]. Proc ASCO 1998, 17:101a. These 30-month follow-up data from the phase III CALGB 9344 trial demonstrate a 5% improvement in disease-free survival and a 3% improvement in overall survival among node-positive breast cancer patients who received sequential adjuvant therapy with AC followed by paclitaxel versus AC alone.

    Google Scholar 

  11. Mamounas EP: Evaluating the use of paclitaxel following doxorubicin/cyclophosphamide in patients with breast cancer and positive axillary nodes. Presentation at the National Institutes of Health Consensus Conference: Adjuvant Therapy for Breast Cancer. Bethesda, MD, November 1–3, 2000. http://consensus.nighgov/cons/114/114_abstract.pdf

  12. Taxol [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2000.

  13. Norton L: Of mice, telomerase, and PTEN. Presentation at the Presidential Symposium: Multidisciplinary Approach to Treating Breast Cancer at the at the 38th Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, May 18–21, 2002 http://www.asco.org These 6-year follow-up data from the phase III CALGB 9344 trial continue to demonstrate significantly higher overall and disease-free survival for adjuvant AC followed by paclitaxel versus AC alone.

  14. National Surgical Adjuvant Breast and Bowel Project: The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: preliminary results from NSABP Protocol B-27 [abstract]. Breast Cancer Res Treat 2001, 69:210.

  15. Buzdar AU, Singletary SE, Theriault RL, et al.: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999, 17:3412–3417.

    PubMed  CAS  Google Scholar 

  16. Buzdar AU, Singletary SE, Valero V, et al.: Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 2002, 8:1073–1079.

    PubMed  CAS  Google Scholar 

  17. Hutcheon AW, Heys SD, Miller ID, et al., for the Aberdeen Breast Group: Improvements in survival in patients receiving primary chemotherapy with docetaxel for breast cancer: a randomised controlled trial [abstract]. Breast Cancer Res Treat 2001, 69:298.

    Google Scholar 

  18. Smith IC, Heys SD, Hutcheon AW, et al.: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002, 20:1456–1466.

    Article  PubMed  CAS  Google Scholar 

  19. Early Breast Cancer Trialists’ Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998, 352:930–942.

    Google Scholar 

  20. Peto R: EBCTCG: Updated results from September 2000 worldwide overview [abstract]. Eur J Cancer 2000, 36(Suppl 5):S47.

    Google Scholar 

  21. National Surgical Adjuvant Breast and Bowel Project: NSABP Clinical Trials Overview: Protocol B-30. http://www.nsabp.pitt.edu/B-30.htm This three-arm phase III trial will provide further insight into the relative efficacy of sequential versus concurrent docetaxel-based adjuvant therapy for node-positive breast cancer.

  22. Swain SM: Phase III randomized study of adjuvant doxorubicin and cyclophosphamide followed by docetaxel versus doxorubicin and docetaxel versus doxorubicin, docetaxel, and cyclophosphamide in women with breast cancer and positive axillary lymph nodes. Protocol CTSU, NSABP-B-30. http://www.cancer.gov A second three-arm phase III trial that will provide further insight into the relative efficacy of sequential versus concurrent docetaxel-based adjuvant therapy for node-positive breast cancer.

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Mayo Clinic Jacksonville, 4500 San Pablo Road, 32224, Jacksonville, FL, USA

    Edith A. Perez MD

Authors
  1. Edith A. Perez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perez, E.A. Adjuvant therapy approaches to breast cancer: Should taxanes be incorporated?. Curr Oncol Rep 5, 66–71 (2003). https://doi.org/10.1007/s11912-003-0089-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-003-0089-4

Keywords

Search

Navigation